Market Cap 1.75B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 11,445,301
Avg Vol 6,971,710
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 76%
Beta 1.18
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
PorkchopSquats
PorkchopSquats Jun. 5 at 11:52 AM
1 · Reply
bonecrack_benny
bonecrack_benny Jun. 5 at 11:03 AM
$ABCL 🚀
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 5 at 3:29 AM
$ABCL if you missed the call it further went into detail about the better outlook on safety and potential increase in efficacy compared to competitors. Posed the ideas of using 635 for oncology induced hot flashes. Spoke again on trying to find a partnering company for 575 or ending the progress at phase 1. Blockbuster potential with what they think for VMS related to menopause could reach $300 million in sales annually at lower projection. All signs support good readouts and strong future.
0 · Reply
tradersunion353
tradersunion353 Jun. 4 at 11:23 PM
$ABCL overhyped underperforming junk 5 years of underperformance
2 · Reply
tradersunion353
tradersunion353 Jun. 4 at 7:58 PM
$ABCL POS rarely moves but struggles to hold its gains as if this POS is up by 500% in last few years.. Such a dissapointment for long term investors
4 · Reply
Slowhorses
Slowhorses Jun. 4 at 7:38 PM
$PSNL $ABCL $OSCR Categories are different but overall "HEALTHCARE" is on the rise.
0 · Reply
Gjhf2782
Gjhf2782 Jun. 4 at 7:12 PM
$ABCL Not selling any shares outright, but sold 32 6/18 call options at $6 & $7 strike price to hedge a little and for some easy income. Equates to 10% of my shares. Also holding 55 long-dated $3 call options for Jan 2028. The odds are definitely in our favor for some good trial results, but I’m expecting some volatility until then. I’ve been holding since around the IPO, so I still have some shares bought in the $20’s. We’ll get back there eventually. Regeneron 2.0 in my opinion.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 4 at 6:52 PM
$ABCL i will only sell if the trial fails or we hit $111 (achievable with $20B revenue - 8-10 pipeline drugs to market or partnership)
3 · Reply
ra1980
ra1980 Jun. 4 at 6:07 PM
$ABCL will it break now i have 1000 shares bought them in 2023 at 5.8 $🤐🤐🤐
0 · Reply
snowPOW
snowPOW Jun. 4 at 5:47 PM
$ABCL this is still on the mat. I'm waiting until it gets up, then I'll get excited. Still looks positive.
0 · Reply
Latest News on ABCL
AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 24 days ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 24 days ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 4 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 2 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 10 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575


AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 11 months ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera assumed with an Outperform at Leerink

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


PorkchopSquats
PorkchopSquats Jun. 5 at 11:52 AM
1 · Reply
bonecrack_benny
bonecrack_benny Jun. 5 at 11:03 AM
$ABCL 🚀
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 5 at 3:29 AM
$ABCL if you missed the call it further went into detail about the better outlook on safety and potential increase in efficacy compared to competitors. Posed the ideas of using 635 for oncology induced hot flashes. Spoke again on trying to find a partnering company for 575 or ending the progress at phase 1. Blockbuster potential with what they think for VMS related to menopause could reach $300 million in sales annually at lower projection. All signs support good readouts and strong future.
0 · Reply
tradersunion353
tradersunion353 Jun. 4 at 11:23 PM
$ABCL overhyped underperforming junk 5 years of underperformance
2 · Reply
tradersunion353
tradersunion353 Jun. 4 at 7:58 PM
$ABCL POS rarely moves but struggles to hold its gains as if this POS is up by 500% in last few years.. Such a dissapointment for long term investors
4 · Reply
Slowhorses
Slowhorses Jun. 4 at 7:38 PM
$PSNL $ABCL $OSCR Categories are different but overall "HEALTHCARE" is on the rise.
0 · Reply
Gjhf2782
Gjhf2782 Jun. 4 at 7:12 PM
$ABCL Not selling any shares outright, but sold 32 6/18 call options at $6 & $7 strike price to hedge a little and for some easy income. Equates to 10% of my shares. Also holding 55 long-dated $3 call options for Jan 2028. The odds are definitely in our favor for some good trial results, but I’m expecting some volatility until then. I’ve been holding since around the IPO, so I still have some shares bought in the $20’s. We’ll get back there eventually. Regeneron 2.0 in my opinion.
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 4 at 6:52 PM
$ABCL i will only sell if the trial fails or we hit $111 (achievable with $20B revenue - 8-10 pipeline drugs to market or partnership)
3 · Reply
ra1980
ra1980 Jun. 4 at 6:07 PM
$ABCL will it break now i have 1000 shares bought them in 2023 at 5.8 $🤐🤐🤐
0 · Reply
snowPOW
snowPOW Jun. 4 at 5:47 PM
$ABCL this is still on the mat. I'm waiting until it gets up, then I'll get excited. Still looks positive.
0 · Reply
Ckkung71
Ckkung71 Jun. 4 at 5:41 PM
$ABCL Don’t be a chicken stay to 10$ at least
0 · Reply
8008track
8008track Jun. 4 at 5:18 PM
$ABCL not sure how anyone is bearish here. If you think abcl635 won’t work, then fine. Otherwise, they are doing everything right. Conserving capital, building a pipeline, professing, clean ph1, updating investors, etc. it’s a bit like watching paint dry sometimes but then when it’s dry, it’s dry. The point is, these guys are on the right path. Could be a true global company.
0 · Reply
MrFish
MrFish Jun. 4 at 5:14 PM
$ABCL "potential blockbuster drug". Awesome presentation. Hopefully the first of money blockbuster drugs to come. Such a cool company..
1 · Reply
MarketBeat
MarketBeat Jun. 4 at 5:03 PM
https://marketbeat.com/a/8692835/ $ABCL AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
0 · Reply
tradersunion353
tradersunion353 Jun. 4 at 4:51 PM
$ABCL Real Long term investors deserve here $20 by september. we waiting 5 years... Ignoring DEMAMP and other clowns who wants this stock to be always trading at 3 dollars so they can and load
1 · Reply
bonecrack_benny
bonecrack_benny Jun. 4 at 4:47 PM
$ABCL Andrew B - What a guy! 👏
0 · Reply
Samb2344
Samb2344 Jun. 4 at 4:46 PM
$ABCL so higher 🚀😂
0 · Reply
JennyRowes
JennyRowes Jun. 4 at 4:40 PM
$ABCL so good.Andrew Booth is a total rockstar
0 · Reply
Buying_Low_Selling_High
Buying_Low_Selling_High Jun. 4 at 4:28 PM
$ABCL I will rewatch the presentation more carefully later but if I got it right the phase 2 is 4 week program with follow-up at 12 week mark. This means they already have 4 week results available. ... can that be the reason for huge price appreciation? ......
1 · Reply
PolarBear1
PolarBear1 Jun. 4 at 4:15 PM
$ABCL Love the way these execs just talk straight. No hype, just facts and real data. If 635 Phase 2 proves the clinical/scientific theory (we’ll know by late September or before) this will be double digits again in no time.
0 · Reply
manojaggarwal
manojaggarwal Jun. 4 at 3:59 PM
$ABCL 🤑
1 · Reply
HumblKing
HumblKing Jun. 4 at 3:52 PM
$ABCL having a nice day
0 · Reply